Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
Rhea-AI Summary
Lantheus (NASDAQ: LNTH) announced that John Wiggins, Vice President, External Manufacturing, will join a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. A live webcast and 30-day replay will be available via the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – LNTH
In the May 27 session, LNTH declined 0.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Radiodiagnostic data | Positive | -1.7% | Announced new PSMA-PET and 18F-GP1 radiodiagnostic data presentations. |
| May 19 | ASCO data presentations | Positive | -0.6% | Detailed new radiopharmaceutical data to be presented at ASCO 2026. |
| May 07 | Q1 2026 earnings | Positive | +5.6% | Reported strong Q1 results, FDA approval of PYLARIFY TruVu, reaffirmed guidance. |
| Apr 23 | Earnings call notice | Neutral | -0.1% | Announced schedule and access details for Q1 2026 earnings call. |
| Mar 17 | PDUFA date extension | Neutral | -0.3% | Disclosed three-month FDA PDUFA extension for LNTH-2501 to June 29, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and data-related news has sometimes seen negative short-term reactions, while strong earnings with guidance support aligned with a notable price gain.
Over the past few months, Lantheus has combined solid financial performance with steady clinical and diagnostic updates. On May 7, 2026, Q1 results showed revenue of $377.3M, GAAP EPS of $1.80, and reaffirmed full-year 2026 guidance, prompting a 5.63% gain. Subsequent announcements about ASCO and SNMMI presentations on new radiopharmaceutical and radiodiagnostic data were followed by modest declines. A PDUFA date extension to June 29, 2026 for LNTH-2501 led to only a small move. Today’s conference appearance fits into this pattern of frequent investor- and science-focused communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
